Conference Coverage

Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse events


 

AT A SYMPOSIUM IN THORACIC ONCOLOGY

Pages

Recommended Reading

Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysis
MDedge Rheumatology
Connective tissue diseases reported in patients receiving immune checkpoint inhibitors
MDedge Rheumatology
Get ready for cancer immunotherapy-induced rheumatic diseases
MDedge Rheumatology
Flu shots may spark immune adverse events in PD-1 blockade for NSCLC
MDedge Rheumatology
SLE linked to subsequent risk of malignant melanoma
MDedge Rheumatology

Related Articles